⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

University Cancer Center Hamburg

h-index: 107
Total citations: 69,446
Total papers: 2,082

Homepage: https://www.uke.de/english/departments-institutes/centers/university-cancer-center-hamburg-(ucch)%E2%80%94hubertus-wald-tumor-center/index.html

Recent papers from University Cancer Center Hamburg

Epigenomic profiling suggests a common origin of both components in mixed gangliocytoma-pituitary neuroendocrine tumorsJournal of Neuropathology & Experimental Neurology · 2026
Selectin-Dependent Organ Invasion and Prognostic Impact of Loss of CD2 in Systemic Mastocytosis2026
Socioeconomic deprivation does not affect survival outcomes in patients with mantle cell lymphoma: evidence from a German nationwide studyBlood Cancer Journal · 2026
Metastatic prostate cancer with neuroendocrine differentiation and liver metastases: prognosis and response to platinum-based chemotherapyWorld Journal of Urology · 2026
ERG inhibition selectively sensitizes ERG-positive prostate cancer to radiation through DNA repair vulnerabilities and enhances response to androgen receptor inhibitorsJournal of Experimental & Clinical Cancer Research · 2026
+A CAR T cell-amplified suppressive B cell circuit in AML2026
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialThe Lancet · 2018
Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC-TRIM registryBritish Journal of Dermatology · 2026
Outcomes of front-line tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a real-world scenarioJournal of Hematology & Oncology · 2026
Current skin of color representation in medical school dermatology education in Germany, Austria and Switzerland (DACH region)JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2026
Insights into the survival impact of delayed immunochemotherapy in newly diagnosed diffuse large B-cell lymphoma: results from a nationwide registry studyBMC Cancer · 2026
Patient willingness to de-escalate adjuvant therapy based on predictive biomarker results in stage IIB-IIID melanoma: A cross-sectional surveyEuropean Journal of Cancer · 2026
Integrated longitudinal analysis of ctDNA, radiologic response, and tumor volume reveals spatial and temporal heterogeneity in advanced melanomaJournal of Translational Medicine · 2026
Socioeconomic disparities in survival among follicular lymphoma patientsScientific Reports · 2026
Incidence and Predictors of Immune‐Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real‐World Cohort StudyInternational Journal of Cancer · 2026
Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trialEuropean Journal of Cancer · 2026
Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myelomaHaematologica · 2026
Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE studyHaematologica · 2026
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trialThe Lancet · 2025
Real-world characteristics and invasive disease-free survival of resected patients with HR-positive/HER2-negative early breast cancer: evidence from German population-based cancer registriesESMO Real World Data and Digital Oncology · 2026